Akceas Tegsedi Approved In Spain To Treat Polyneuropathy In Hereditary Transthyretin Amyloidosis

Akcea Therapeutics Inc, a biopharmaceutical company, announced The Ministry of Health of Spain (MSCBS) has granted approval for the reimbursement of Tegsedi (inotersen) in the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis."We appreciate the Ministry of Health's thorough evaluation of Tegsediand rapid approval to make this treatment option available to people living with hATTR amyloidosis with polyneuropathy in Spain," said Michael Pollock, SVP, head of Europe at Akcea."This milestone highlights the strength of the clinical data supporting Tegsediand the critical need in the hATTR amyloidosis community for a subcutaneous treatment option that allows patients to self-administer at a time and place that works for them. The data from the NEURO-TTR study showing benefits in measures of neuropathy and quality of life underlines the potential of this therapy to benefit patients in the years ahead. We will continue to collaborate with the Ministry of Health to make Tegsediavailable to patients in Spain as soon as possible,”Michael added.Hereditary Transthyretin (hATTR) amyloidosisis an under-recognized, debilitating and progressive disease that is caused by the buildup of TTR proteins that misfold due to inherited genetic mutations. It is characterized by the deposition of amyloid fibrils throughout the body including in nervous tissue and can have a devastating impact on patients' quality of life.Tegsediis a once-weekly, at-home subcutaneous injection that targets the polyneuropathy of hATTR amyloidosis at its source by reducing production of the TTR protein. It is the first antisense medicine available for patients in Spain with hATTR amyloidosis with polyneuropathy, and also the first at-home treatment available to Spanish patients.The Ministry of Health's positive opinion of reimbursement for Tegsediwas based on results from the phase 3 NEURO-TTR study in patients with hATTR amyloidosis with symptoms of polyneuropathy. Results from that study demonstrated that patients treated with Tegsediexperienced significant benefit compared to patients treated with placebo across both co-primary endpoints: the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) and modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression.Tegsedi (Inotersen) was approved by the US Food and Drug Administration (US FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Tegsedi, discovered and developed by Ionis Pharmaceuticals, is the world's first and only subcutaneous RNA-targeting drug designed to reduce the production of human transthyretin (TTR) protein.The approval is based on data from the NEURO-TTR study that was a phase 3 randomized (2:1), double-blind, placebo-controlled, 15-month, international study in 172 patients with hATTR amyloidosis with symptoms of polyneuropathy.In NEURO-TTR, Tegsedidemonstrated significant improvement compared to placebo in measures of neuropathy and quality of life as measured by the modified Neuropathy Impairment Score +7 (mNIS+7) and in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN) total score. Patients treated with Tegsediexperienced similar benefit regardless of subgroups such as age, sex, race, region, Neuropathy Impairment Score (NIS), Val30Met mutation status, and disease stage.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!